💡 律咖编者按：
本文由律咖网社群读者 Xiqinghua 投稿分享。
为了方便大家阅读，律咖网编辑 JingJing（微信：lvga2015）对原文进行了细致的逻辑润色与合规性整理。希望能给正在 荷兰 创业路上的你带来真实的参考。

I’ve been in the Netherlands for just over a year now—running a small business exporting photovoltaic junction boxes from Fujian to Dutch solar installers. I thought I understood “European bureaucracy.” I was wrong.

It wasn’t the paperwork. Not even the language. It was the silence.

Last week, I met with a biotech startup founder in Eindhoven—someone who’d just moved here from Shanghai with a novel enzyme delivery system. She’d been waiting for six months just to get her first meeting with the Dutch Food and Consumer Product Safety Authority (NVWA). Not for a license. Not for funding. Just to ask if her product category even fell under their scope.

She said, “They don’t say no. They just… don’t respond.”

I sat there, sipping lukewarm coffee, thinking: Is this what progress feels like?

The Dream Was Faster

When I first arrived, I read the brochures: “The Netherlands has one of the most business-friendly environments in Europe.” “English-speaking legal infrastructure.” “Startups thrive here.” I believed it. I still do—but now I see the cracks.

Noord-Brabant, especially Eindhoven and Tilburg, is a magnet for life sciences. The Brainport region has €1.8 billion in public-private R&D investment. ASML is here. Philips is here. And yet, according to recent reports from industry forums, prolonged waiting periods have become the norm—not the exception—for biotech startups navigating compliance.

I asked three founders in the same accelerator program:

  • How long did it take to get your first regulatory feedback?
  • One said 11 weeks. Another, 22. The third? “I gave up and moved my pilot to Germany.”

They didn’t complain about taxes. Or visas. Or rent. They complained about time.

The Dutch government boasts a GDP per capita of EUR 63,000—nearly 60% higher than the EU average. Capital is deep. Talent is global. But the systems meant to support innovation seem to be running on a different clock.

What’s Really Causing the Delay?

I don’t have a government insider. But I’ve listened. And here’s what I’ve heard from others in the ecosystem:

  1. Regulatory overload, not lack of will.
    The NVWA, the Central Veterinary Institute, and the Netherlands Enterprise Agency (RVO) are all understaffed. Biotech isn’t just “medical devices” anymore—it’s synthetic biology, gene editing, AI-driven diagnostics. The rules haven’t caught up. So they slow down to avoid mistakes.

  2. The “Dutch way” of consensus.
    In China, we move fast and fix later. Here, they want everyone—scientists, ethicists, civil servants, farmers’ unions—to agree before one form is stamped. It’s beautiful. It’s exhausting.

  3. The “digital sovereignty” effect.
    After the government blocked Kyndryl’s takeover of Solvinity last week—over fears of U.S. control of DigiD data—I started noticing something: the Dutch are becoming more cautious, not less, about foreign involvement. Even in biotech. Even when it’s Chinese-owned. Even when the tech is good.

    I’m not being singled out. I’m just noticing it now.

    My startup doesn’t need government approval to sell junction boxes. But if I ever pivot to biotech packaging materials? I’d need to prove my supply chain doesn’t “pose a possible risk to the public interest.” That’s not a legal term. That’s a feeling.

The Variables No One Talks About

Let’s be honest: the Netherlands isn’t failing. It’s evolving.

  • The influx of international talent has outpaced institutional bandwidth.
  • The rise of dual-use tech—where a bioreactor can also be used for biosecurity research—means every application is now a security review.
  • The political climate is shifting. The “return hubs” plan announced yesterday isn’t just about migration—it’s about control. Sovereignty. Boundaries.

I used to think the Dutch were just… nice. Now I think they’re careful.

And in biotech? Carefulness can cost you years.

I asked a Dutch lawyer in Utrecht: “Is there a faster path?”
He smiled and said: “There’s the legal path. And then there’s the known path. The known path? You find someone who’s done it before. And you pay them to walk you through it.”

I didn’t ask how much.

What I’ve Learned (So Far)

I’m not here to tell you to leave. Or to stay.

But if you’re a founder—especially from Asia—thinking of setting up a biotech operation in Noord-Brabant, here’s what I wish someone had told me:

  1. Start with a facilitator, not a lawyer.
    The Dutch startup visa requires a recognized incubator or accelerator. Don’t skip this. Choose one with biotech experience—like HighTechXL, or YES!Delft. They know the hidden contacts, the internal timelines, the unspoken rules.

  2. Prepare for 6–12 months of silence.
    Your business plan must be flawless. Your funding proof must be bulletproof. But even then? Expect no reply for months. Send one polite follow-up every 45 days. That’s the rule.

  3. Don’t assume English = fast.
    Everyone speaks English. But the forms? The internal memos? The regulatory interpretations? Mostly Dutch. Hire a local compliance assistant—even part-time. It saves more time than you think.

  4. Build relationships before you need them.
    Go to Eindhoven BioBridges meetups. Attend the Brainport Innovation Days. Don’t pitch. Just listen. The people who move the needle aren’t in government offices. They’re in the labs, the cafés, the co-working spaces where people say, “Oh, you’re doing that? My cousin’s lab tried that last year…”

FAQ: Practical Paths for Biotech Founders in Noord-Brabant

Q1: Where do I start if I want to register a biotech startup in the Netherlands?
→ Step 1: Identify a recognized Dutch facilitator (incubator/accelerator) willing to sponsor your startup visa application.
→ Step 2: Prepare a detailed business plan showing innovation (new tech or method not yet in the Dutch market).
→ Step 3: Prove sufficient funding (minimum €45,000 for founder + dependents, plus operational costs).
→ Step 4: Sign a formal agreement with the facilitator.
→ Step 5: Submit through the IND (Immigratie- en Naturalisatiedienst) portal.
→ Key point: The facilitator must be on the official RVO list. Verify here: RVO Startup Visa

Q2: How long does biotech product compliance typically take?
→ There’s no fixed timeline. For novel substances, expect 6–18 months.
→ For medical devices: check the MDR (Medical Device Regulation) pathway via the CGG (Central Government Service for Medical Devices).
→ For non-medical biotech (e.g., enzymes for industrial use): contact NVWA and ask for a “pre-submission meeting.” Bring a Dutch-speaking advisor.
→ Tip: The Dutch Biotech Network maintains a public list of “experienced reviewers.” Find it here: Dutch Biotech Network

Q3: Can I use my Chinese company’s data for regulatory submissions?
→ Possibly—but expect scrutiny.
→ The Dutch authorities increasingly require local validation: lab reports from Dutch-certified institutes, local safety data sheets (SDS) in Dutch, and proof of ethical oversight.
→ Do not assume your Chinese GMP certificate will be accepted.
→ Pathway: Partner with a Dutch CRO (Contract Research Organization). Many offer “regulatory bridging” services.

I used to think entrepreneurship was about speed. Now I think it’s about patience.

The Netherlands doesn’t reward the loudest. It rewards the quiet ones who show up, again and again, with better forms, better questions, better relationships.

I’m still sleep-deprived. Still chasing time zones. Still wondering if I’ll ever make this work.

But I’m here.

Because I’ve seen what happens when you leave: the talent goes. The innovation follows. The ecosystem shrinks.

Maybe the Dutch aren’t slow. Maybe they’re just building something that lasts.

Maybe different people will have different answers.

If you’ve been through this—whether you’re in Eindhoven, Nijmegen, or just thinking about it—I’d love to hear how you navigated the silence.

You can find me on the律咖网 community group. Or, if you want to talk about Noord-Brabant, biotech compliance, or just how to survive 4am Zoom calls with Wuhan suppliers—feel free to add JingJing on WeChat: lvga2015. No promises. No sales pitch. Just real talk.

🔸 延伸阅读

🔸 Netherlands Blocks US Takeover of Vital Digital Supplier 🗞️ 来源: Slashdot – 📅 2026-05-26
🔗 阅读原文

🔸 Netherlands’ ASML plans to onboard 1,000 employees as client demand surges 🗞️ 来源: Chinanationalnews – 📅 2026-05-26
🔗 阅读原文

🔸 Netherlands Greenlights Plan for Migrant ‘Return Hubs’ Outside E.U. 🗞️ 来源: Breitbart – 📅 2026-05-26
🔗 阅读原文

请知悉：律咖网（Lvga.com）是跨境创业公开信息与内容分享平台，不提供法律、税务、会计或合规服务。
本文内容基于公开资料，并由人工编辑与 AI 工具协助整理，仅供信息参考之用，不构成任何法律、投资、移民或商业决策建议。
政策可能随时间变化，请以官方渠道与当地持牌专业人士意见为准。
如内容有需要修订之处，欢迎随时与我联系。